Patent ID: 9585914
Date: 2017-03-07
CPC Classifications: A61K,A61P,C12N

Claim:
1. A method of treating multiple myeloma by administering to a patient, a composition comprising natural killer (NK) cells produced by: (a) isolating NK cells from peripheral blood or bone marrow of a patient suffering from multiple myeloma, and (b) expanding the isolated NK cells ex vivo in the presence of autologous mononuclear cells for about 20 days, in a serum-free stem cell growth medium comprising human albumin, human recombinant insulin, L-glutamine and β-mercaptoethanol (CELLGRO SCGM), wherein said medium is supplemented with anti-CD3 antibody, human serum, and IL-2 for about the first 5 days, and wherein said medium is supplemented with IL-2 and human serum for the remainder of the about 20 days, whereby the expanded said NK cells have: